Evaluation of dose-volume histograms after prostate seed implantation: 4-Year experience

Strahlentherapie und Onkologie

Volumn 180, Issue 9, 2004, Pages 550-556

  Hoinkis, Cordelia ^a   Hakenberg, Oliver W ^a   Lehmann, Dietmar ^a   Winkler, Cornelia ^a   Wirth, Manfred P ^a   Herrmann, Thomas ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Brachytherapy; DVH; Permanent implants; Prostate cancer; Treatment planning

Indexed keywords

IODINE 125; PALLADIUM 103;

ACCURACY; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; EVALUATION; HISTOGRAM; HUMAN; IMPLANT; IMPLANTATION; LEARNING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATION; ORGAN SIZE; PRESCRIPTION; PROSTATE CANCER; RADIATION DOSE; RADIOISOTOPE THERAPY; TRANSRECTAL ULTRASONOGRAPHY;

BODY BURDEN; BRACHYTHERAPY; DIAGNOSIS, COMPUTER-ASSISTED; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MALE; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; PROSTHESIS IMPLANTATION; QUALITY ASSURANCE, HEALTH CARE; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 4544369132     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-1337-8     Document Type: Article

References (32)

1. Al-Qaisieh B, Ash D, Bottomley DM, et al. Impact of prostate volume evaluation by different observers on CT-based post-implant dosimetry. Radiother Oncol 2002;62:267-73.
2. Al-Qaisieh B, UK Prostate Brachytherapy Group. Pre- and post-implant dosimetry: an inter-comparison between UK prostate brachytherapy centres. Radiother Oncol 2003;66:181-3.
3. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, Hrsg. Krebs in Deutschland, 4. überarb. u. aktualisierte Ausgabe. Saarbrücken, 2004 (www.rki.de/6BE/KREBS).
4. Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-21.
5. Bice WS Jr, Prestidge BR, Grimm PD, et al. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;41:921-7.
6. Dubois DF, Prestidge BR, Hotchkiss LA, et al. Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. Radiology 1998;207:785-9.
7. Hakenberg OW, Wirth MP, Hermann T, et al. Recommendations for the treatment of localized prostate cancer by permanent interstitial brachytherapy. Urol Int 2003;70:15-20.
8. Han BH, Wallner K, Merrick G, et al. The effect of interobserver differences in post-implant prostate CT image interpretation on dosimetric parameters. Med Phys 2003;30:1096-102.
9. Helmick R, Tarver R, Chan R, et al. Evaluation of post-plan dosimetry using TRUS and CT after transperineal prostate seed implant. Med Dosim 2002;27:289-93.
10. 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130:283-6.
11. Kaulich TW, Lamprecht U, Paulsen F, et al. Physical basics and clinical realization of interstitial brachytherapy of the prostate with iodine 125. Strahlenther Onkol 2002;178:548-55.
12. Lee WR, deGuzman AF, Bare RL, et al. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 2000;46:83-8.
13. Martin T, Baltas D, Kurek R, et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 2004;180:225-32.
14. Matzkin H, Kaver I, Bramante-Schreiber L, et al. Comparison between two iodine-125 brachytherapy implant techniques: pre-planning and intraoperative by various dosimetry quality indicators. Radiother Oncol 2003;68:289-94.
15. Merrick GS, Butler WM, Dorsey AT, et al. Seed fixity in the prostata/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 2000;46:215-20.
16. Moerland MA, Wijrdeman HK, Beersma R, et al. Evaluation of permanent 1-125 prostate implants using radiography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1997;37:927-33.
17. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-97.
18. Nag S, Bice W, de Wyngaert K, et al. The American Brachytherapy Society recommendations for permanent prostata brachytherapy postimplant dosimetry analysis. Int J Radiat Oncol Biol Phys 2000;46:221-30.
19. Nath R, Anderson LA, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 1995;22:209-34.
20. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001;50:605-14.
21. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 2004;71:29-33.
22. Prestidge BR, Bice WS, Prete JJ, et al. A dose-volume analysis of permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 1997;39:289.
23. Ragde H, Blasko JC, Grimm PD, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442-53.
24. Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998;83:989-1001.
25. Stock RG, Stone NN, Tabert A, et al. A dose-response study for 1-125 prostate implants. Int J Radiat Oncol Biol Phys 1998;41:101-8.
26. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003;57:929-43.
27. Trotti A, Byhardt R, Stetz J, et al. Common Toxicity Criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
28. Wachter S, Wachter-Gerstner N, Bock T, et al. Interobserver comparison of CT and MRI-based prostate apex definition. Clinical relevance for conformal radiotherapy treatment planning. Strahlenther Onkol 2002;178:263-8.
29. Williamson JF, Coursey BM, DeWerd LA, et al. Recommendations of the AAPM on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription. Med Phys 2000;27:634-42.
30. Willins J, Wallner K. CT-based dosimetry for transperineal 1-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1997;39:347-53.
31. Wirth MP, Hermann T, Alken P, et al. Recommendations for treatment with permanent, interstitial brachytherapy alone in locally limited prostate cancer. Strahlenther Onkol 2002;178:115-9.
32. Zelefsky MJ, Whitmore WF. Long-term results of retropubic permanent 125-iodine implantation of the prostate for clinically localized prostate cancer. J Urol 1997;158:23-9.